Close Menu

Breaking News

The Novodiag COVID-19 real-time PCR assay enables on-demand and fully automated detection of early COVID-19 infections in about one hour, the firm said.

The firm said as part of a development study it is using a gut microbiome analysis tool developed in collaboration with Thermo Fisher Scientific.

The PCR-based assay is designed to detect RNA from the virus' nucleocapsid and ORF1ab genes in upper and lower respiratory specimens.

Q1 revenues totaled $6.23 billion, up from $6.13 billion in Q1 2019 and beating the consensus analyst estimate of $6.17 billion.

Emergency testing related to the SARS-CoV-2 pandemic strongly increased, but routine testing declined due to fewer regular health checks.

The test was already authorized for use in Canada and South Korea. Seegene has sold more than 10 million of the assay in more than 60 countries.

The company said that despite the uptick, the COVID-19 pandemic has negatively affected orders for its Cologuard colorectal cancer screening test.

The collaborators will use a protein microarray comprising the SARS-CoV-2 proteome as well as an ELISA to develop and test vaccine candidates.

With $2.5 million in initial philanthropy funding, the consortium plans to launch several research projects and establish a data commons for storing and sharing results. 

The newly launched EndPandemic National Data Consortium brings together seven life sciences and bioinformatics firms in search of treatments and vaccines.

The Cold Spring Harbor Laboratory spinout will build predictive models for lung cancer progression and risk using its SpliceCore software platform.

As part of the deal, Applied DNA will permanently place robotic and diagnostic equipment at the hospital to enable validation of the test.

The firms are pairing Personalis' comprehensive cancer genomics technology with Indivumed's multiomic database, hoping to improve the insights gleaned from banked samples.

The institute will use Curetis' Unyvero Hospitalized Pneumonia panel on high-risk patients admitted to the ICU for COVID-19 pneumonia.

The firms will evaluate Stratafide, a pan-solid tumor diagnostic test designed to identify actionable genomic alterations in tissue or blood samples.

The test, which is used to screen for cervical cancer, was previously approved by the agency for use with the Cobas 4800 system.

The test is designed to detect SARS-CoV-2 E and RDRP genes in nasal, nasopharyngeal, and oropharyngeal swabs, as well as bronchoalveolar lavage specimens.

The firm is dedicating the proceeds from the CHF 25 million it has raised overall in Series C financing to market and product expansion, including US market entry.

Several labs and at least one company have been working on assays that add samples directly to the PCR reaction and don't require RNA extraction, a time-consuming step.

The test is expected to run on Tangen's GeneSpark nucleic acid amplification platform and achieve a CLIA waiver for use in doctors' offices.

By tapping into available population sequence and single-cell RNA sequence data, researchers are attempting to understand SARS-CoV-2 susceptibility.

The company holds and licenses a variety of IP related to high-throughput genotyping, sample pooling, and methods involved in oligonucleotide ligation-based assays.

Blueprint Genetics, recently acquired by Quest Diagnostics in January, will base the 600-gene panel on its whole-exome sequencing capability.

A new analysis from a UCSD-led team has found that the mutation affecting the ACTL6B gene affects chromatin accessibility and transcription activity.

Researchers described ancestry patterns, apparent population interactions, and genetic turnover during the late Neolithic and early Bronze Age.

Pages

Bloomberg reports the US Centers for Medicare & Medicaid Services sent Orig3n a letter saying it has not corrected lab issues uncovered in an earlier inspection.

In an editorial at BMJ Opinion, two genetic counselors call for an increased focus on post-test patient care.

A new survey finds people in the US are getting their COVID-19 test results back faster, but not fast enough to help some viral control measures, NPR reports.

In PLOS this week: genomic analysis of malaria parasites in Ethiopia, loci linked to childhood BMI, and more.